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Abstract: Prader-Labhart-Willi syndrome (PWS) is a rare genetic disorder characterized by intel-
lectual disability, behavioural problems, hypothalamic dysfunction and specific dysmorphisms.
Hypothalamic dysfunction causes dysregulation of energy balance and endocrine deficiencies, in-
cluding hypogonadism. Although hypogonadism is prevalent in males and females with PWS,
knowledge about this condition is limited. In this review, we outline the current knowledge on the
clinical, biochemical, genetic and histological features of hypogonadism in PWS and its treatment.
This was based on current literature and the proceedings and outcomes of the International PWS
annual conference held in November 2019. We also present our expert opinion regarding the diag-
nosis, treatment, care and counselling of children and adults with PWS-associated hypogonadism.
Finally, we highlight additional areas of interest related to this topic and make recommendations for
future studies.
Keywords: Prader-Willi syndrome; hypogonadism; child; adult; review; diagnosis; treatment; substi-
tution
1. Introduction
Prader-Labhart-Willi syndrome (PWS) is a rare genetic disorder resulting from a lack
of expression of the paternally derived chromosome, 15q11-q13. The clinical entity was
described for the first time by Andrea Prader, Alexis Labhart and Heinrich Willi in 1956
and was called Prader-Labhart-Willi syndrome. Prader being a pediatric endocrinologist,
Willi a gynaecologist and Labhart an adult endocrinologist-together overseeing the three
principal periods of life with different clinical presentations of people with PWS. Over
time the name of Labhart disappeared, apparently while in the United States the name
was judged as too long. The middle name disappeared while it seemed less important and
some people thought Willi was the first name of Professor Andrea Prader (personal com-
munication Prader-Eiholzer). PWS is characterised by intellectual disability, behavioural
problems and a hypothalamic dysfunction combined with specific dysmorphisms [1–3].
Hypothalamic dysfunction causes growth hormone deficiency, hypogonadism, and a dys-
regulation of energy balance associated with hypoactivity and insatiable hunger that results
in increased fat and decreased muscle mass. In addition to controlling nutrient intake and
enhancing physical activity, the beneficial effects of early treatment of growth hormone
deficiency in PWS have been demonstrated: short stature is normalised and muscle mass
enhanced [4,5]. Hypogonadism is distinct in males because sexual maturation stops at
the early to mid-puberty stages [6]. This condition is less apparent in most girls, since
an almost complete maturation and breast development occurs. However, spontaneous
menarche is rather unusual [6]. While growth hormone therapy has been broadly accepted
as a standard treatment in PWS, supplementing gonadal hormones is a matter of debate
since the early 90s, mainly because of the presumed associated behavioural changes. Nev-
ertheless, supplementing gonadal hormones is thought to be effective and beneficial for
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improving health and quality of life in PWS [7]. As part of the International Prader-Willi
Syndrome Organisation annual conference held in Cuba in November 2019, a workshop
dedicated to share experiences on gonadal function, puberty, sexuality and fertility in PWS
confirmed the need for more information. Consequently, this paper aims to describe the
current knowledge on hypogonadism in PWS children and adults with respect to diagnosis
and treatment, based on current literature and the outcomes of this meeting. We present
our expert opinion on the treatment, care and counselling of children and adults with
PWS-associated hypogonadism.
2. Nature and Extent of Hypogonadism in PWS
2.1. Normal Sexual Development
Normal sexual development is the result of genetic factors, sexual hormones and germ
cell production. Puberty involves the growth and maturation of gonads (testes and ovaries)
and the appearance of sexual characteristics (e.g., sexual hair and breast development).
In general, breast development in girls and testicular enlargement in boys (>3 mL) are
the first signs of normal pubertal development. During puberty, menstruation and the
onset of sperm emission occurs. The changes in puberty are caused by increased gonadal
sex steroid secretion, primarily oestrogen in females and testosterone in males. Increased
gonadal activity occurs because of increased stimulation by the pituitary gonadotropin
luteinising hormone (LH) and follicle stimulating hormone (FSH).
Hypogonadism is the condition in which the production of sex hormones and germ cells
are inadequate because of primary gonadal failure (primary hypogonadism) or hypothalamic
pituitary dysfunction (secondary hypogonadism). Hypogonadism can be evident either at
birth (e.g., indicated by clitoral hypoplasia in girls and micropenis and cryptorchidism in
boys) or later in life (e.g., failure to enter puberty or complete sexual maturation).
2.2. Sexual Development in PWS
2.2.1. Clinical Aspects
At birth, the prevalence of cryptorchidism and scrotal hypoplasia ranges from 75% to
95% [6,8–11]. Micropenis or small penis is reported to occur in males at rates of between
78% to 90%. In girls, the respective rates of clitoris and labia minora hypoplasia are 93%
and 88% [9,11]. In contrast, Hirsch et al. reported normal penile length in infancy and
early childhood, but small penile size in adulthood [6]. In the original description, Prader,
Labhardt and Willi stated that puberty was delayed and incomplete [1]. The age of onset
for boys is typically normal, but tends to show pubertal arrest at a mean chronological
age of 13.5 years with a mean testicular volume of 4 mL and decelerating growth velocity;
pubic hair growth reaches Tanner Stages 3–5 at this time due to premature pubarche [7].
In girls, the onset of puberty with breast development occurs at a normal age [6,12],
although precocious puberty has been presented in several case reports [6,13,14]. While
further development is delayed, Tanner Stage 5 development is usually noted past the
normal age of 15.5 years [12]. Pubic hair developed early (i.e., Tanner Stages 4–5) in all
girls studied [6]. Vaginal bleeding generally occurs between 13 and 34 years (mean age,
20) [6], although Siemensma et al. reported a mean age of 14.9 years at menarche for a
sample of five girls (age range, 12.7–16.7) [12]. After menarche, regular bleeding are rare
and oligomenorrhea is most prevalent. Some have bleedings, most likely caused by the
unopposed action of oestrogens originating from adipose tissue [6].
Until now, there are no reports on PWS men having fathered a child, but evidence
exists of at least seven pregnancies in women with PWS [15].
2.2.2. Biochemical Aspects
In 1956, Prader and colleagues first reported low urinary 17-ketosteroid excretion
in older males and concluded that testosterone levels were low [1]; they also measured
increased gonadotropin secretion. Further work established a normal minipuberty in boys,
associated with normally elevated LH, FSH and testosterone levels within the first few
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months of life [7,16]. Until puberty, inhibin B, LH and FSH levels remain at the lower end
of the normal concentration ranges. At the onset of puberty, testosterone levels increase but
remain low. Both LH and FSH also increase: LH levels usually only reach the low regions
of the normal range and FSH levels are normal to high. Conversely, inhibin B levels decline
to low and even undetectable levels in adulthood. This pattern is, together with the low
anti-Müllerian hormone (AMH) serum levels, indicative of a primary testicular defect. The
fact that LH and FSH levels do not increase to high levels could be interpreted as partial
hypogonadotropic hypogonadism [6–8,17–19].
Siemensma et al. [12] reported on girls with PWS from 6 months until 22 years. AMH
was normal, indicating the presence of primordial follicles. LH and oestrogen levels
were normal before the age of 10 years. Thereafter, LH and FSH increased within the
normal range, although LH was relatively low considering the low oestrogen levels and
FSH relatively high. After 15 years, oestrogen levels were lower than in normal girls,
LH levels were normal, and FSH slightly elevated. Inhibin B levels fell in the lower
region of the normal range and inhibin A levels low to normal; small antral follicles were
normally present, but with signs of impaired follicle maturation. AMH concentrations
varied between normal to lower levels of the normal range. The authors interpreted
their results as partial hypogonadotropic hypogonadism. Gross-Tsur et al. [16] outlined
several patterns of hypogonadism in 16 adolescent and adult females (aged between 16
and 34 years) with varying combinations of primary (hypergonadotropic) and central
(hypogonadotropic) hypogonadism. Concentrations of FSH and inhibin B were the most
useful criteria to characterize the type of hypogonadism. Hirsch [6] added to the findings
in adult women that inhibin B varied over time and was low or undetectable in the majority.
Nonetheless, normal levels can be found, indicating potential fertility; repeat measurements
are therefore recommended for contraceptive measures.
The type of hypogonadism-hypogonadotropic or hypergonadotropic or a combination
of these-becomes apparent only in late adolescence or early adulthood and appears to
stabilise after the age of 20 years [6,8].
2.2.3. The Role of Orchidopexy
Eiholzer et al. [7] found that levels of gonadotrophins were not significantly different
in boys with or without cryptorchidism until the age of 18 months. Inhibin B levels were sig-
nificantly decreased after infancy. A specific gene expressed in testes (C15orf2) that lies on
the PWS region of chromosome 15 might be involved in normal spermatogenesis and there-
fore explain the infertility and low inhibin B levels in boys and adult males with PWS [20].
There is no relation between age at orchidopexy and inhibin B levels, which suggests that
cryptorchidism does not play a major role in hypergonadotropic hypogonadism.
2.2.4. Interaction
The question has been raised as to whether the growth hormone deficiency present in
PWS contributes to impaired gonadal function. Growth hormone substitution was shown
to potentiate the Leydig cell response to human chorionic gonadotropin (hCG) in patients
with hypopituitarism or hypogonadotropic hypogonadism [21,22]. Nevertheless, an arrest
of gonadal development is still observed in all boys at pubertal age, despite otherwise
efficacious growth hormone treatment [23].
The cause of cryptorchidism is not well established. Minipuberty is normal in PWS and
associated with normal gonadotrophin and testosterone levels, and in utero testosterone
levels are normal. Insulin-like factor-3 (INSL-3) protein is also adequately expressed in
testes in PWS. Therefore, other factors have been suggested, for example that diminished
abdominal pressure could hamper testicular descent, such as that observed in prune belly
syndrome [7,17].
A candidate gene to the cause of hypothalamic hypogonadism, could be the necdin
gene located on the human chromosome 15q and its chromosome 7-equivalent in mice. Loss
of gene function in mice might result in impaired development of gonadotropin-releasing
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hormone neurons. Expression in the ovary is then important for factors involving oocyte
development [24]. Another candidate is the melanoma antigen L2 (MAGEL2) gene and its
lack of expression, which results in less ovulation in mice with smaller litter sizes-this gene
is expressed in the hypothalamus [25].
Regarding the rare event of true precocious puberty observed in PWS, an imprinted
gene coding for MKRN3 (makorin RING-finger protein 3) has been identified and is located
in the critical region for PWS on chromosome 15 [26].
2.2.5. Histological Aspects
There are few reports on gonadal histology in PWS. Vogels et al. [27] reported de-
creased and absent spermatogonia in testicular biopsies from eight prepubertal boys with
PWS and one adult with only Sertoli cells. Katcher et al. [28] reported the absence of
spermatogonia in PWS and also in males with well-descended testes. Matsuyama et al. [29]
performed testicular biopsies during orchidopexy for cryptorchidism; spermatogonia was
classified in nine boys (mean age, 2.2 years) and showed favourable histology in only two
samples (Nistal I) and seven with unfavourable histology (Nistal scores II and III) where
three had Sertoli cell-only syndrome. In all adults, LH and FSH levels were elevated and
testosterone low.
After the onset of puberty when Sertoli cells mature, inhibin B production becomes
dependent on normal spermatogenesis. Thus, inhibin B decreases when spermatogenesis
does not take place.
There are two case reports on females with PWS: (1) an autopsy of a 21-year-old
woman showed the lack of ovarian follicle development [30], whereas (2) examination of
an ovary obtained from a 32-year-old woman during a caesarean birth revealed normal
follicles in all stages of development [15].
2.3. Treatment
2.3.1. Supplementing Gonadal Hormones in Normal Male and Female Hypogonadism
We searched PubMed with emphasis on publications from the last years using the
keywords: “hypogonadism”, “treatment”, “substitution” in combination with the “similar
articles” and “cited by” tools to retrieve current treatment guidelines as basis for the next
section. In primary hypogonadism (or hypergonadotropic hypogonadism), sex hormone
substitution with oestrogens or testosterone is considered the mode of treatment. For the
treatment of central hypogonadism (i.e., hypogonadotropic hypogonadism), gonadotropic
factors (LH and FSH) offer the potential to improve fertility in cases where this aspect is
the primary therapeutic aim. Controlled trials on pubertal induction in normal male and
female hypogonadism are virtually absent and current practice is based on expert opinion.
The aim is to induce secondary sexual characteristics, increase muscle mass, establish peak
bone mass and maximise final (adult) height. After induction, long-term sex hormone
substitution is required to maintain normal serum sex hormone levels, sexual function,
bone density and general well-being.
Boys and men. Most knowledge gained on the initiation and progression of pubertal
development has been made with the application of intermediate-acting esters of testos-
terone (testosterone enanthate and testosterone cypionate) or a mixture of very short and
short-acting esters (Sustanon®) [31,32]. A key case study from the group of Prader de-
scribed the effects of puberty induction with androgens in 21 boys with bilateral anorchia,
including a discordant pair of identical twins [33]. Long-acting testosterone enanthate
(100 mg/month) was administered at a bone age of 12.8 years and continued with a higher
dose of 250 mg/month by a bone age of 14.5 years; this regimen resulted in normal growth
and pubertal progression in the affected twin, which was comparable to his normal twin
brother. Most guidelines recommend an initial monthly intramuscular testosterone ester
dose of 50 to 100 mg with gradual increases in dose over the course of 18–24 months for the
induction of puberty in boys [34]; alternatively transdermal testosterone (10 mg) or oral
testosterone undecanoate (40 mg). This generally recommended procedure induces sec-
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ondary sexual characteristics and maximises final (adult) height [35]. In adults, dosages are
individualised based on serum testosterone levels and well-being. A typical intramuscular
testosterone ester dose is 250 mg every 3 weeks or 1000 mg every 10–14 weeks. Evaluation
of mood is often recommended as changes can occur. Therapeutic levels for testosterone
are reported to range from 450 to 600 ng/dL. In obese men, sex hormone-binding globulin
(SHBG) and resultant testosterone levels can be low. Therefore, it is recommended to also
measure free testosterone levels and SHBG in order to decide whether free testosterone
should be measured to monitor and tailor therapy [36]. Haemoglobin levels should also
be monitored as there is a risk of erythrocytosis when testosterone levels are too high.
To monitor the effect of testosterone on the prostate, regular prostate specific antigen
measurements are recommended after the age of 40 years.
Girls and women. Most evidence on the induction of puberty with oestrogens in girls
has been gathered in Turner syndrome. While it is more common to begin therapy from
12 years of age, the earliest time to treat is reported at 10 years-more recent studies point to
the advantages of an earlier onset of therapy in terms of final height, cognitive development
and uterine maturation [37,38]. Nevertheless, the appropriate age to start hormone substitu-
tion remains a matter of debate. Consensus only exists on the initial application of low-dose
oestrogens (i.e., one-eighth to one-quarter of the recommended adult dose), which can be
gradually increased at intervals of 6–12 months. Monitoring focuses either on the clinical
effect (Tanner stage, bone age and uterine growth) or by applying the ultrasensitive oestra-
diol assay. The route of administration is oral or preferably transdermal to eliminate the
first pass effect in the liver. The use of low dose oestradiol formulations (e.g., 0.1 mg daily)
is important. Transdermal oestradiol administration begins at low doses (0.05–0.07 µg/kg
nocturnally). In older girls, the starting dose can range from 0.08 to 0.12 µg/kg and is
slowly increased over 12–24 months, after which time cyclic gestagen is added (or after the
first menstrual bleed) to maximise breast development. In adulthood, oestradiol is typically
given orally (at a dose of 1–2 mg) or transdermally (50 µg patch) as a maintenance dose
with a cyclic progestin regimen to avoid endometrial hyperplasia [34]. These preparations
were developed for the supplementation of sex steroids in post-menopausal women and
therefore, dosages are lower compared to the endogenous oestrogen production in normal
eugonadal women. It is unnecessary to administer cyclic progestins every month, and
nowadays it is believed that less frequent withdrawal bleeding (e.g., every fourth month)
is equally safe regarding the risk of endometrial cancer.
2.3.2. Aims of Supplementing Gonadal Hormones in PWS
In PWS, supplementing gonadal hormones seems to be equally important not only
because of the positive biological effects on muscle mass, strength, activity and bone
density, but also regarding the psychosocial quality of life. Substitution has favourable
effects on young men especially affected by the typical childish appearance with a lack
of facial hair growth and voice break. For some girls and women, it is important to have
menses. Oestrogen substitution also provides a concomitant contraceptive measure against
unintended pregnancies that many parents wish to avoid.
Parents and caretakers want to see the lives of their children and adolescents progress
smoothly and especially wish to avoid any associated drawbacks of increased aggressive
behaviour as that seen in PWS boys and men. In girls, these drawbacks include any gain in
fat mass and the hygienic aspects associated with menstruation.
2.3.3. Outcome from Published Trials on Supplementing Gonadal Hormones in PWS
Supplementing gonadal hormones has only been studied in boys and men. Six boys
with PWS were treated with hCG (Pregnyl®) for 2 years to induce puberty. The dosage
regimen was dependent on bone age (e.g., 500 I.U. twice weekly for a bone age ranging
from 13 to 13.5 years and 1000 I.U. twice weekly for a higher bone age of 13.6 to 14.5 years).
This mode of treatment led to a rapid and sustained increase in testosterone levels (although
still within the lower limit of normal), an adult pubic hair pattern and deepening of the
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voice. In one boy, complete testicular descent occurred during therapy. Testicular volume
only slightly increased (max. 6 mL). FSH and LH levels decreased, and inhibin B remained
below the normal range. It was concluded that fertility was not achieved during hCG
therapy. Lean body mass increased and percentage fat mass did not decrease significantly
during treatment. Behaviour was assessed and revealed pre-existing problems known in
PWS: problems in social interaction, aggressiveness and irritability or rapid mood changes.
These aspects did not change during therapy or were not markedly different from the
pubertal changes observed in brothers and sisters [7,23].
Kido et al. [39] treated 22 adolescents and adults (aged 16 to 48 years) with hypog-
onadism (Tanner Stage less than 4 and testosterone level below 10.4 nmol/L) for 2 years
with a relative low dose of 125 mg testosterone given intramuscularly per month. Dur-
ing treatment, the amount of pubic hair increased in 17 subjects, but characteristics on
penile length and testicular volume were not documented. Erectile function and ejaculation
were reported in eight and three subjects, respectively. Sperm content was negligible in
semen samples collected from three subjects. Testosterone, LH and FSH levels remained
unchanged throughout the 2-year study period. Body fat percentage decreased, and bone
mineral density (BMD) and lean body mass increased. Behaviour was unchanged using the
Modified Overt Aggression scale (MOAS). Behavioural problems (including shouting an-
grily, throwing objects around and skin picking) were already evident prior to beginning the
study; testosterone treatment continued regardless of the observed behavioural problems.
In conclusion, the data on supplementing gonadal hormones in PWS are rather limited,
confined to a single study for each age group, and behavioural problems did not increase
during substitution therapy.
2.3.4. Proposed Schedules for Supplementing Gonadal Hormones in PWS
While most children are treated nowadays with growth hormone under the super-
vision of a multidisciplinary team of health professionals, height, weight for height and
body image have all improved. Based on this development, substitution of sex steroids
has received great attention that has resulted in further proposals being made on how to
advance the treatment of PWS hypogonadism in young subjects. Conversely, experience
and recommendations for gonadal substitution in adults are sparse, most likely because
most adults did not undergo this type of treatment in their childhood. We modified our
search strategy described above to search specifically within PWS.
Most of the recommendations are based on expert opinion and the few studies reported
in this paper. Heksch et al. [40] proposed beginning treatment for boys with a dose of
50–100 mg testosterone intramuscularly from the age of 14 years, if there is evidence of
pubertal arrest. The initial dose can be gradually increased until the “typical” adult male
dose of 250 mg/4 weeks is reached. For girls, hormone supplementation begins when
there is no breast development by 13 years, pubertal progress stops, or menarche has not
occurred by 16 years. Dose recommendations are not given, except that oral oestrogens
should be administered in graduated doses with concomitant oral contraception after
the onset of the first menstrual bleed. Hirsch et al. [6] proposed testosterone substitution
in boys from 15–16 years. The working group of Bakker [41] recommend sex hormone
supplementation from an age of 11 years in girls and 14 years in boys, unless there is
normal progression of puberty; this is thought to prevent the decline in BMD, which they
observed in PWS children treated with growth hormone hGH after the pubertal age.
At our institution, we administer testosterone at a mean age of 13.5 (12.5–15.5) years,
when pubertal arrest becomes obvious in boys. Details are provided in Table 1. From a
group of 27 boys and men, we delayed or discontinued treatment in seven subjects because
of extreme (yet pre-existent) behavioural problems.
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13–14.5 100 mg/4 weeks
>14.5 250 mg/4 weeks





Cyclic dosing of with E2 2 mg/day E2 for 12 days, followed by
2 mg E2 + norethisterone acetate 1 mg for the next 10 days and
1 mg E2 for the last 6 days
E2, oestrogen.
In girls, we recommend the induction of puberty when development stops. If puberty
induction is necessary in girls, we begin at the age of 11.5 years. Details on the doses
used are provided in Table 1. If puberty progresses, we most often start at the age of
14.5 years, usually when the girl expresses their desire to menstruate. The mean age was
13.3 (10–17) years in a total of 28 girls and women, where 22 underwent sex steroid supple-
mentation at our clinic. Half were treated because of pubertal arrest and the remainder
wanted to have menses. Half of the entire group stopped oestrogen supplementation
because they no longer wanted to continue their menstrual cycle. We agreed with this
strategy because BMD was normal (U.E., personal communication, December 2019).
For sex steroid-naïve adults, Kido et al. [39] recommends supplementation with
monthly 125 mg testosterone injections, which are considered useful, safe and do not
negatively affect behaviour.
2.4. Discussion and Prospects
From the current literature, it is clear that hypogonadism is frequent in boys and girls
with PWS. Spontaneous puberty occurs more often in girls than boys and fertility and
pregnancies have been reported in women only, in contrast, as a rule, men are infertile.
The cause of the hypogonadism is mixed with a preponderance of primary hypogonadism,
although varying combinations of primary and central hypogonadism are seen. PWS
is a rare condition, therefore it is not surprising that controlled studies on the diagnosis
and treatment of hypogonadism are absent. Observational studies, expert opinions and
experience from treating patients with other conditions provide the evidence that forms a
basis for our practice. From a biological point of view, supplementation of sex steroids is the
way to proceed in improving body composition and bone mass as well as accomplish sexual
maturation and develop as normal adolescents and people. Therefore, as a general rule,
all PWS patients with hypogonadism should receive supplementation with sex steroids to
induce puberty in children and adolescents and maintain normal physical development
and health in adults when hypogonadism is diagnosed. In our opinion, sex steroid-naïve
adults should also be offered supplements.
Nowadays, growth hormone treatment begins at a fairly young age, and catch-up
growth is usually accomplished by most children when they reach the pubertal age. This
suggests that final height will not be compromised by the induction of puberty at a normal
age. Therefore, from a biological point of view, induction of puberty could take place
from the age of 11 years in girls and 13 years in boys. When we consider the status of
intellectual disability and delayed psychological maturation, one might consider inducing
at a later age. However, the question arises as to when children and adolescents with PWS
will achieve the appropriate age of maturity to deal with the effects of inducing puberty.
Experience drawn from conditions such as Turner syndrome reveals good acceptance of
the onset of (induced) puberty. Overall, we advocate the induction of puberty at the normal
pubertal age, while taking into consideration that the starting age could be individualized
based upon biological and psychological factors for children with PWS.
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The main reason for the induction of puberty is to avoid the deceleration of growth and
bone maturation. The observed deceleration in height velocity can provide a reliable clinical
sign of hypogonadism particularly in boys, which can be ascertained by the absence of
pubertal onset or progress and measurement of serum gonadotrophin and sex steroid levels.
Further reasons for initiating and maintaining sex steroid supplementation are to achieve
complete sexual maturation, an appropriate muscle mass and normal peak bone mass. In
our experience, a normal appearance as an adult is especially very important for young
adults with PWS. Data on the evolution of lean body mass and fat mass during growth
hormone treatment show a body composition with a lower fat mass and higher lean body
mass compared to that without treatment [4,5,42,43]. We have not found any published data
on the effects of pubertal induction and sex steroid supplementation on the evolution of
lean body mass and muscle mass after beginning sex steroid supplementation. In our own
study, we could not demonstrate an increase in lean body mass after pubertal induction
in boys with PWS. However, the effect on muscle mass is depending on physical activity,
which was not examined, and long-term data are missing [23]. In terms of bone mass
and BMD, a longitudinal study in children with PWS reported a decrease in BMD during
growth hormone therapy after pubertal age when sex steroids were not supplemented [41].
In a 2-year observational study including young adults with PWS, Donze et al. showed
an increase in BMD in young adults on sex steroid supplementation versus a decrease in
those without sex steroid supplementation [44]. Therefore, supplementation of sex steroids
could be important in normalising and maintaining BMD and peak bone mass. Whether
this proposition has clinical relevance is not clear, although there is speculation on an
increased fracture risk in adults with PWS [45,46]. In hypogonadal adults, the negative
effects of withholding sex steroid supplementation on BMD and fracture risk are obvious,
apparently through a combined effect of the absence of testosterone and oestrogens on
bone metabolism [47].
The arguments against induction of puberty or starting sex steroid supplementation
are also based on biological and psychological (i.e., behavioural) factors. Biological aspects
encompass the event of spontaneous puberty or age-appropriate serum levels of sex
steroids. Relative contraindications are previous thromboembolism, severe hypertension or
a familial history of breast cancer. Psychological contraindications include active psychosis
and behavioural problems, the latter being a relative contraindication. The biological
contraindications are comparable to those outlined for sex steroid supplementation in
post-menopausal women and Turner syndrome or the use of oral contraceptive pills in
normal women. In PWS, the levels of sex steroids are normalised by supplementation and
consequently, the pre-existent elevated risk for thromboembolic events in PWS [48] and the
pre-existent risk for breast cancer are not increased. Furthermore, hormone replacement
therapy (HRT) with oestradiol is commonly used in PWS instead of alkyl oestradiol, the
active ingredient in contraceptive pills that have a different safety profile. Oestradiol has a
beneficial effect on cardiovascular function (e.g., hypertension), and epidemiological and
basic science studies do not support the commonly held assumption that HRT increases
the risk of thrombosis [49]. The psychological and psychosocial considerations are specific
for PWS, and behavioural problems are part of the PWS phenotype. We would like to
raise two points on this subject: Firstly, behavioural problems seem to remain constant
throughout childhood and the adolescent years. The few reports on induction of puberty
and sex steroid supplementation do not present any increase in behavioural problems.
We have also seen that there is no relevant change in behavioural problems at the start of
or during sex steroid supplementation. In some adults, we observed the disappearance
of mood swings after administering sex steroids. Secondly, there is a development in all
PWS adolescents towards increased autonomy that can result in more conflict situations
with parents and caretakers. Yet these events are also prevalent during normal pubertal
development. This situation can be mistaken for aggressive behaviour in PWS subjects
who often have less verbal and intellectual abilities to express their feelings and opinions.
Parents and guardians, but also physicians, are often reluctant to start sex steroid treatment
Int. J. Mol. Sci. 2021, 22, 2705 9 of 12
because the view is still held that testosterone leads to aggressive behaviour, although
this is a fallacy. We generally consider biological contraindications as comparable to those
encountered in normal girls and women, which should not affect supplementation of sex
steroids in PWS. Behavioural problems should not be regarded as contraindications for the
treatment with sex steroids.
The dose for induction of puberty in boys and girls with PWS can follow the schemes
used in normal boys with hypogonadism and girls with Turner syndrome, respectively.
These doses can be increased gradually every year over the course of 2 to 3 years until
the adult doses are reached (Table 1). We, among other clinicians, did not use the same
adult dose of testosterone in men with PWS but used about 75% of the dose used in
normal men with hypogonadism. There is no basis or evidence for this policy and from
a biological point of view, the application of a lower dose is inconsistent. We therefore
suggest prescribing the same adult starting dose of testosterone to men with PWS and
personalising the maintenance dose as in normal men with hypogonadism. In some men
with visceral obesity, it might be better to monitor free testosterone levels during treatment
for tailoring treatment [36]. In adolescents and women who are potentially fertile (e.g.,
inhibin B levels above 20 pg/mL), contraceptive measures should be taken; we prescribe
an oral contraceptive pill in these cases.
An important issue in the treatment process is to decide whether to start and if so,
when is the timing optimal. We believe supplementation should be started when growth
decelerates around the pubertal age (at 13–14 years in boys and at 11–12 years in girls)
or pubertal progress stops. This is applicable for most boys and about half of the girls.
Naturally, the age at treatment initiation should be individualized based on biological
and psychological factors. Measurement of serum sex steroid and gonadotrophin levels
can provide additional information. Most of the remaining children and adolescents will
show signs of hypogonadism at a later stage, whereby girls mostly have amenorrhea or
oligomenorrhea. Who should be involved in this discussion? We think the discussion
should be initiated by the physician before pubertal age has been reached. Information on
the purpose, side effects, timing and decision process regarding supplementation therapy
should be provided through direct consultation with the patient and guardians that is
confirmed with a written report. When the physician decides that the time has come to start
sex steroid supplementation, they should discuss the matter with the parents to organise
how the child should be involved and who is responsible for informing the patient. In fact,
it is preferable for the child or adolescent to be involved in the discussion and be active in
making the final decision on whether treatment will take place and when. Appropriate
monitoring of the therapeutic effects should be gathered. In Table 2, we provide a proposal
for the measurements to be considered before starting and during supplementation of sex
steroids. Close communication between children and adolescents with their parents and
caretakers is necessary to ensure the smooth initiation of treatment and that reassurance can
be provided during conflict situations. Another important issue focuses on how we should
deal with the issue of women and their choice to stop oestrogen supplementation and
menstruation. Longitudinal data on the development of BMD are needed to better counsel
these women regarding whether and in which form sex steroids should be supplemented.
This review clearly shows that the evidence on hypogonadism in PWS and its treat-
ment is limited. There are several questions to be solved regarding the biological and
psychosocial effects of sex steroid supplementation. The long-term treatment effects on
muscle mass and peak bone mass have yet to be studied and are important in supporting
any future decisions on extended supplementation of sex steroids in PWS. Until these
answers are established, we suggest supplementing sex steroids for hypogonadism in
PWS in a similar manner to that for “normal” hypogonadism to prevent osteoporosis,
sarcopenia and its negative consequences. A reliable and specific instrument to assess and
rate behaviour in children and people with PWS in a longitudinal setting is lacking. We
propose the development of a simple behavioural scale that may enable us to study the
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effect of sex steroid supplementation on behaviour among centres of excellence around the
world by gathering sufficient data to solve this important issue.
Table 2. Examination strategy for sex steroid supplementation in PWS patients at our institution.
at Start after 1 Year after 2 Years Long Term,Every 2 Years
Boys







Lab LH, FSH, T, E2,inhibin B, Hb, Hct T, E2, Hb, Hct
LH, FSH, T, E2,
inhibin B, Hb, Hct T, E2, Hb, Hct
Bone age + + + + 2
DXA + + + 3
Girls








LH, FSH, T, E2,
inhibin B, AMH,
liver panel
LH, FSH, T, E2,
inhibin B,
liver panel
LH, FSH, T, E2,
inhibin B,
liver panel
LH, FSH, T, E2,
inhibin B, AMH,
liver panel
Bone age + + + + 2
DXA + + + 3
1 Behavioural scale to be developed, simple instrument to objectively measure behaviour. 2 until final height. 3 from age = 30 years every 5
years. AMH, anti-Müllerian hormone; DXA, Dual-energy X-ray absorptiometry; E2, oestrogen; FSH, follicle stimulating hormone; Hb,
haemoglobin; Hct, haematocrit; Ht, height; LH, luteinising hormone; PubSt, pubertal stage; T, testosterone; Wt, weight.
2.5. Conclusions
Hypogonadism is prevalent in PWS, especially in males, and should be appropriately
treated. Most of the evidence on the diagnosis and treatment of this condition is primarily
based on expert opinion. In principle, we suggest initiating substitution with sex hormones
at a similar age and using similar dosage regimen as that for normal hypogonadal children
and adolescents. There are only a few absolute contraindications for substitution. Concerns
about promoting aggressive behaviour are based on anecdotal reports. Normal maturation
and striving for autonomy, which takes place during puberty should not be confused with
aggression. We provide our expert opinion on the diagnosis, treatment and monitoring of
hypogonadism in PWS. Further studies on treatment effects on muscle mass, (peak) bone
mass and behavioural changes are needed to develop the best possible strategy for the
diagnosis and treatment of hypogonadism in PWS.
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